Arrowhead Pharmaceuticals stock analysis
Arrowhead Pharmaceuticals (HDP1) Stock Price & Analysis
HDP1 Stock Chart & Stats
- Day’s Range
- EUR 43.86 - EUR 44.54
- 52-Week Range
- EUR 32.68 - EUR 78.04
- Previous Close
- EUR 43.38
- Volume
- N/A
- Average Volume (3M)
- 186
- Market Cap
- EUR 6.24B
- Enterprise Value
- EUR 11.46B
- Total Cash (Recent Filing)
- EUR 1.60B
- Total Debt (Recent Filing)
- EUR 864.07M
- Price to Earnings (P/E)
- ―
- Beta
- 0.97
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -1.37
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Phase III Clinical Efficacy
Consistent, substantial triglyceride reductions across two pivotal studies provide strong clinical validation for plozasiran. This efficacy can support regulatory approval, physician adoption, and a durable position in serious cardiometabolic indications if commercial execution continues.
Regulatory And Approval Momentum
Broad approvals establish a regulatory foundation across major markets, while the priority review voucher could accelerate access to an expanded indication. Earlier availability would improve commercialization timing and allow the company to capture demand sooner.
Revenue And Partnership Growth
Strong year-over-year revenue growth demonstrates that Arrowhead can monetize its platform through partnerships while building product sales. Upfront and milestone-related collaboration income also helps fund development and validates external interest in its pipeline.
Bears Say
Persistent Operating Losses
Deep operating and net losses show that revenue growth has not yet translated into sustainable earnings. Continued spending on research and commercialization could prolong losses, requiring successful launches, partnerships, or other funding sources to support the business.
Negative And Volatile Cash Generation
Negative trailing cash generation and inconsistent conversion indicate that reported revenue is not yet supporting ongoing investment needs. If cash burn persists, Arrowhead may have less flexibility to advance its pipeline or absorb additional commercial and clinical costs.
Early Commercial Ramp And Market Education
A gradual adoption curve could delay the point at which REDEMPLO becomes a meaningful financial contributor. Extensive education, payer engagement, and commercial expansion may require sustained investment before demand reaches a scale capable of offsetting the company’s high costs.
Arrowhead Pharmaceuticals News
Arrowhead’s Plozasiran Trial Completion Signals a Pivotal Moment for ARWR Investors
Arrowhead Pharmaceuticals, Inc. ($ARWR) announced an update on their ongoing clinical study. Arrowhead Pharmaceuticals, Inc. has completed a Phase 3 study called “Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the
Arrowhead’s Plozasiran Hits Phase 3 Completion: What Investors Should Watch Next
Arrowhead Pharmaceuticals, Inc. ($ARWR) announced an update on their ongoing clinical study. Arrowhead Phase 3 Update: Plozasiran Targets Severe Triglycerides This Phase 3 study, officially titled “Double-blind, Placebo-controlled, Phase 3
Arrowhead’s Plozasiran Trial Completion Marks a Key Catalyst in the Triglyceride Market
Arrowhead Pharmaceuticals, Inc. ($ARWR) announced an update on their ongoing clinical study. Arrowhead Pharmaceuticals, Inc. (ARWR) has completed a Phase 3 study called “Double-blind, Placebo-controlled, Phase 3 Study to Evaluate
HDP1 FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
What is Arrowhead Pharmaceuticals’s market cap?
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Is Arrowhead Pharmaceuticals overvalued?
Does Arrowhead Pharmaceuticals pay dividends?
What is Arrowhead Pharmaceuticals’s EPS estimate?
How many shares outstanding does Arrowhead Pharmaceuticals have?
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Arrowhead Pharmaceuticals Stock Smart Score
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher R. Anzalone
- Employees
- 711
- Website
- arrowheadpharma.com
- Address
- 177 East Colorado Boulevard, Pasadena, CA, 91105, US
Arrowhead Pharmaceuticals (HDP1) Earnings & Revenues
HDP1 Earnings Call
Earnings Call SentimentPositive
The call was decidedly positive on clinical and strategic fronts: landmark Phase III SHASTA-3/4 results (deep TG reductions and major reductions in acute pancreatitis), broad regulatory approvals, accelerating commercial traction in FCS, strong partnership revenue and a robust pipeline with multiple near-term data catalysts. Offsetting items include increased net losses and higher operating spend as Arrowhead scales R&D and commercial infrastructure, a sizable near-term cash payment for a priority review voucher ($215M), and the fact that commercial product revenues remain small today. Overall, management portrayed the financial investments as deliberate and tied to significant near-term derisking and value-creation events.
View all DE:HDP1 earnings summariesHDP1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |
